Technology | Heart Valve Technology | August 15, 2017

FDA Clears Aortic Annuloplasty Device for Bicuspid Aortic Valve Repair

The FDA cleared the HAART 200 Aortic Annuloplasty Device for bicuspid aortic valve repair. The devioce is made by BioStable Science and Engineering Inc.

Aug. 15, 2017 — The U.S, Food and Drug Administration (FDA) granted market clearance for the HAART 200 Aortic Annuloplasty Device, the first annuloplasty device designed specifically for bicuspid aortic valve repair. With FDA clearance of both the HAART 300 and HAART 200 Aortic Annuloplasty Devices, BioStable Science and Engineering Inc. is now able to offer U.S. surgeons a comprehensive portfolio of aortic valve repair solutions that addresses all forms of aortic valve insufficiency. 

A Bicuspid aortic valve (BAV) is a congenital malformation where the aortic valve forms with only two functional valve leaflets instead of the normal three. BAV is the most common congenital heart defect, affecting up to 2 percent of the population, and carries significant risk of cardiovascular complications. Patients with BAV have significantly higher risk of developing aneurysms or dissections of the aorta and approximately 53 percent of patients will require aortic valve replacement within 25 years of being diagnosed.[1] Most BAV patients undergo aortic valve replacement between 40 and 60 years of age, subjecting them to increased risk of re-operation or complications associated with valve replacement technologies. Aortic valve repair is an emerging surgical alternative for patients with bicuspid aortic valve insufficiency that may offer improved patient outcomes compared to valve replacement.[2]

The HAART 200 Aortic Annuloplasty Device is designed to facilitate valve repair in patients with aortic valve insufficiency due to BAV. The device is designed to reduce annular diameter based upon leaflet size, to conform the annulus to a circular, symmetric shape for improved valve function, and to stabilize the annular geometry long-term.

“Surgical repair of the bicuspid aortic valve can be a complex three dimensional problem because of variability in the valve anatomy,” explained Scott Rankin, M.D.,  professor of surgery at West Virginia University Heart and Vascular Institute, and inventor of the HAART device. “Implantation of the HAART 200 Aortic Annuloplasty Device conforms the native valve to the three dimensional shape of the device, creating a circular valve geometry and aligning the leaflet commissures into the preferred 180 degree orientation. Conforming the native valve to this shape simplifies assessment and reconstruction of the valve leaflets and creates a central flow pattern of blood through the valve which may improve the long-term durability of the repair.”

The HAART 200 Aortic Annuloplasty Device is not available for sale outside of the United States.

For more information: www.biostable-s-e.com

Read the article "HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use."

Read the related article "Transcatheter Annuloplasty For Repair Versus Replacement in Functional Mitral Regurgitation."
 

References: 

1. Michelena HI1, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA. 2011 Sep 14;306(10):1104-12.

2. Vallabhajosyula P, Szeto WY, Habertheuer A. et al. Bicuspid aortic insufficiency with aortic root aneurysm: root reimplantation versus Bentall root replacement. Ann Thoracic Surg 2016;102:1221-8.

 


Related Content

News | Cardiovascular Surgery

January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under ...

Home January 29, 2024
Home
News | Cardiovascular Surgery

January 11, 2024 — Paragonix Technologies, a pioneer in organ transplant solutions, is proud to announce the publication ...

Home January 11, 2024
Home
News | Cardiovascular Surgery

December 20, 2023 — The Smidt Heart Institute at Cedars-Sinai has opened an Aortic Surveillance Clinic for the ...

Home December 20, 2023
Home
News | Cardiovascular Surgery

December 18, 2023 — The Department of Cardiovascular Surgery at The Mount Sinai Hospital has received the highest ...

Home December 18, 2023
Home
News | Cardiovascular Surgery

November 2, 2023 — The University of Maryland Medical Center (UMMC) released a statement on the passing of a patient ...

Home November 02, 2023
Home
News | Cardiovascular Surgery

October 25, 2023 — Edwards Lifesciences announced new data from the PARTNER 3 trial demonstrating continued low rates of ...

Home October 25, 2023
Home
News | Cardiovascular Surgery

October 18, 2023 — A study published in The Annals of Thoracic Surgery demonstrates outstanding long-term survival ...

Home October 18, 2023
Home
News | Cardiovascular Surgery

October 18, 2023 — Walgreens and the Cardiovascular Research Foundation (CRF) announced a collaboration to drive forward ...

Home October 18, 2023
Home
News | Cardiovascular Surgery

April 21, 2023 — A Michigan Medicine study finds that Black and socioeconomically disadvantaged patients with a common ...

Home April 21, 2023
Home
News | Cardiovascular Surgery

March 24, 2023 — The American College of Surgeons (ACS), with the Society for Vascular Surgery (SVS), has launched a new ...

Home March 24, 2023
Home
Subscribe Now